GENELINK SIGNS LETTER OF INTENT FOR LICENSING AGREEMENT WITH UNICITY NETWORK
April 18, 2002

Margate, NJ-(BUSINESS WIRE)-- April 18, 2002- GeneLink BioSciences, Inc. (OTCBB:GNLK) announced today that it has signed a letter of intent with Unicity Network of Orem, UT (A Division of Royal Numico) to enter into a licensing agreement for GeneLink's genetic profiling technology for skin care. This licensing agreement would allow Unicity to utilize GeneLink's patented DNA Collection Kit® and genetic profiling technologies by providing its distributors with an innovative line of personalized skin care products. Further details were not disclosed.

Unicity Network was created by the unification of two of the most highly successful companies in the nutritional and direct-selling industries, Rexall Showcase International and Enrich International. For more information about Unicity visit its website at www.unicitynetwork.com. 

"Unicity Network has a sterling worldwide reputation and a history of product innovation," says John DePhillipo, CEO of GeneLink. "We admire how Unicity's Independent Business Owners help consumers identify their needs and find the best products to meet those needs. GeneLink is delighted to be a part of Unicity's expansion into new markets. "

"Capitalizing on innovations for our Independent Business Owners is one of the key ways Unicity helps Make Life Better," says Richard Bizzaro, Chairman and CEO of Unicity Network. "These skin care breakthroughs by GeneLink will provide significant advantages to our people. The products will help them Look Better through exciting new technology, and the products will help them Live Better by generating new customer interest for their independent businesses."

GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service has developed a proprietary method for genetic assessments (patents pending) and is beginning to license these breakthrough nutragentic and dermagentic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement and health care industries. For more information about GeneLink, visit its website at www.genelink.info.

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.